March 19, 2013
San Francisco Business Times
Five Prime, UCB team up on search for drugs
Five Prime Therapeutics Inc. and Belgian drug developer UCB S.A. will work together to discover biologic targets and drugs to treat fibrosis-related inflammatory diseases and central nervous system disorders.
South San Francisco's Five Prime could receive about $16 million from an upfront fee, technology access fees, research funding and research milestones. It also could receive other fees from UCB, product-related milestone payments and royalties on global sales of products tied to each protein licensed from Five Prime's library of about 5,600 proteins.
UCB has an option to license exclusive rights to selected protein targets.
To read the full article, visit: http://www.bizjournals.com/sanfrancisco/blog/biotech/2013/03/five-prime-ucb-fibrosis.html